Moderna Inc. is cutting about 10% of its workforce, part of an effort by the struggling biotech company to reduce spending as sales of its Covid vaccine decline.

The layoffs come as Moderna’s cash position has raised worries on Wall Street that the company may need to raise new capital.

Moderna Inc. (NASDAQ: MRNA) has announced plans to reduce its global workforce by approximately 10% by the end of the year due to decreasing COVID-19 vaccine sales and market uncertainty.

Moderna (MRNA) stock in focus as the company plans to cut 10% of its workforce by 2025 amid cost-saving efforts. Read more here.

Moderna said on Thursday it would trim roughly 10% of its global workforce and have fewer than 5,000 employees by the end of the year, as the biotech accelerates its cost-cutting efforts amid ...

Massachusetts-based Moderna said it plans to cut 10% of its global staff as part of its ongoing efforts to reduce annual operating expenses by around $1.5 billion by 2027.

Moderna will cut around 10% of its global workforce by year-end to reduce costs, as Covid vaccine sales decline. It aims for 8 new product approvals by 2027.

Moderna has announced a new cost-cutting round as it tries to pare down its annual costs, with a new commitment to cut 10% off its headcount by the end of the year. The target is to reduce its ...

CAMBRIDGE, Mass. — Massachusetts-based vaccine maker Moderna on Thursday announced plans to cut its workforce by approximately 10%. Moderna CEO Stéphane Bancel notified employees of the decision.

[CAMBRIDGE, MASSACHUSETTS] Moderna is cutting about 10 per cent of its workforce, part of an effort by the struggling biotech company to reduce spending as sales of its Covid vaccine decline. In a ...

Massachusetts-based Moderna said it plans to cut 10% of its global staff as part of its ongoing efforts to reduce annual operating expenses by around $1.5 billion by 2027.